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OBJECTIVES We sought to define the clinical picture and natural history of familial arrhythmogenic right
ventricular cardiomyopathy (ARVC).
BACKGROUND Arrhythmogenic right ventricular cardiomyopathy is a myocardial disease, often familial,
clinically characterized by the impending risk of ventricular arrhythmias and sudden death.
METHODS Thirty-seven ARVC families of northeast Italy were studied. Probands had a histologic
diagnosis of ARVC, either at autopsy (19 families) or endomyocardial biopsy (18 families).
Protocol of the investigation included basal electrocardiogram (ECG), 24-hour ECG,
signal-averaged ECG, stress test and two-dimensional Doppler echocardiography. Invasive
evaluation was performed when deemed necessary.
RESULTS Of the 365 subjects, 151 (41%) were affected, 157 (43%) were unaffected, 17 (5%) were
healthy carriers, and 40 (11%) were uncertain. Mean age at diagnosis was 31 6 13 years. By
echocardiography, 64% had mild, 30% had moderate, and 6% had severe form. Forty percent
had ventricular arrhythmias, 49 were treated with antiarrhythmic drugs, and two were treated
with implantable cardioverter defibrillators. Sport activity was restricted in all. Of the 28
families who underwent linkage analysis, 6 mapped to chromosome 14q23-q24, 4 to
1q42-q43, and 4 to 2q32.1-q32.3. No linkage with known loci was found in four families and
10 had uninformative results. During a follow-up of 8.5 6 4.6 years, one patient died (0.08
patient/year mortality), and 15 developed an overt form of ARVC.
CONCLUSIONS Arrhythmogenic right ventricular cardiomyopathy is a progressive disease appearing during
adolescence and early adulthood. Systematic evaluation of family members leads to early
identification of ARVC, characterized by a broad clinical spectrum with a favorable outcome.
In the setting of positive family history, even minor ECG and echocardiographic abnormal-
ities are diagnostic. (J Am Coll Cardiol 2000;36:2226–33) © 2000 by the American College
of Cardiology
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a primary myocardial disease frequently associated with
left bundle branch block (LBBB) ventricular arrhythmias
and sudden death in young people (1–5). Familial forms
have been reported since 1982 (1,6–8), and in 1988 we
published a study of nine families with ARVC, suggesting a
pattern of autosomal dominance and variable penetrance
with a polymorphic phenotype (7). Several loci have been
found so far, suggesting a genetic heterogeneity (9–14).
None of the involved gene defects has yet been identified,
and a role for apoptosis in provoking the progressive death
of myocytes has been postulated (15). More recently, a
defect of the gene for plakoglobin has been found in the
recessive form associated with palmoplantar keratoderma
(16).
Many questions remain unanswered, including the true
incidence, the age at onset and the rate of progression of the
disease. Moreover, clinical diagnosis, natural history and
risk stratification remain challenging. Some subjects are
asymptomatic all their life, while others present with ar-
rhythmic sudden death as the first manifestation of the
disease. Congestive heart failure (CHF), which may mimic
dilated cardiomyopathy and require heart transplantation, is
an unusual manifestation (17).
Thirty-seven families affected by ARVC from northeast
Italy were systematically studied and followed up over a long
period in order to clarify these issues.
METHODS
Definition. According to World Health Organization
classification (18), ARVC is “characterized by progressive
fibrofatty replacement of right ventricular (RV) myocar-
dium, initially with typical regional and later global RV and
some left ventricular (LV) involvement, with relative spar-
ing of the septum. Familial disease is common, with
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autosomal dominant inheritance and incomplete pen-
etrance; a recessive form has been described. Presentation
with arrhythmias and sudden death is common, particularly
in the young.”
Criteria for diagnosis. Published criteria for ARVC (19)
are subdivided into major and minor criteria and are
classified into six categories based on the identification of
the following: 1) global and/or regional dysfunction and
structural alterations, 2) fatty or fibrofatty replacement
of the RV free wall, 3) repolarization abnormalities, 4)
depolarization/conduction abnormalities, 5) arrhythmias,
and 6) family history. The diagnosis of ARVC is based on
the presence of two major criteria; one major, plus two
minor criteria; or four minor criteria. Subjects examined
before publication of these criteria were retrospectively
reviewed.
Family history is a major criterion when there is autopsy
evidence of ARVC in a family member, and a minor
criterion when there is a history of sudden death in a family
member #35 years with suspected or clinically diagnosed
ARVC.
Study population. The study began in 1980 and enrolled
37 families affected by ARVC. Eleven of these families have
been the object of clinical and genetic studies previously
reported (5,7–10,12). There were 365 members (201 male,
164 female), mean age 28.6 6 12.7 years. Mean follow-up
duration was 8.5 6 4.6 years (range, 2 to 18 years).
All the probands had a histologic diagnosis of ARVC,
either at autopsy or at RV endomyocardial biopsy (four to
five samples from the free wall).
In 19 families, the proband (13 male and 6 female, mean
age 27 6 10.5 years) died at a young age, and the diagnosis
was made at autopsy. Eight of the 19 probands who died
suddenly have been reported in previous pathologic publi-
cations (2,4). In the remaining 18 families, the proband (14
male and 4 female, mean age 25 6 10 years) is still alive and
presented with ventricular arrhythmias: nonsustained ven-
tricular tachycardia (VT) in 8, sustained VT in 9 and
ventricular fibrillation (VF) in one case. These 18 patients
underwent RV and LV angiography, as well as RV endo-
myocardial biopsy, which were all diagnostic for ARVC.
Study protocol. The following noninvasive investigations
were routinely performed: clinical examination, chest X-ray,
12-lead electrocardiogram (ECG), 24-h ambulatory ECG,
signal-averaged ECG (SAECG), stress test and two-
dimensional and Doppler echocardiography. The use of
SAECG and two-dimensional echocardiogram was started
in 1985; thus, subjects not previously evaluated with these
tests had these investigations thereafter.
Forty-seven affected family members with either sus-
tained or nonsustained VT had catheterization and contrast
angiography with endomyocardial biopsy and electrophysi-
ologic studies. Results of these investigations have been
reported previously (20–25).
Patients were classified as affected or unaffected. Subjects
with minor clinical findings, insufficient for diagnosis using
the Task Force criteria (21), were classified as uncertain.
Based on pedigree analysis, patients without clinical evi-
dence of the disease but able to transmit it to their progeny
were classified as healthy carriers.
During follow-up, patients who had a history of sustained
VT, nonsustained VT or frequent premature ventricular
beats (PVBs) were assessed every six months by clinical
examination, ECG, 24-h ambulatory ECG, SAECG and
echocardiography; the remaining patients were evaluated
every 12 months. Subjects classified as uncertain were
assessed every 12 months, and unaffected subjects were
assessed every 12 months if age #25 years and every 24
months if age 25 to 35 years, to eventually leave the
follow-up after the age of 35 years. The echocardiogram was
done with a phased-array ultrasound system (Hewlett Pack-
ard model 1500) with duplex 2.0 to 2.5-M/Hz transducer
for imaging, spectral Doppler and color flow mapping,
including M Mode, two-dimensional and Doppler echocar-
diography as previously described in detail (26–29). Exam-
inations were evaluated independently by two observers for
the presence of abnormal wall motion and regional struc-
tural abnormalities in the RV and LV, including size and
ejection fraction. Agreement of interobserver analysis for
segmental wall motion was found in 98% of the visualized
segments; discrepancies were resolved by consensus.
Patients affected were subdivided by echocardiography
investigation into three groups according to RV end-
diastolic volume (RVEDV): 1) mild form—a normal or
slightly increased RVEDV (,75 ml/m2) with localized
hypokinetic or akinetic areas, in the presence or absence of
trabecular disarrangements and thickened, hyperechogenic
or dense moderator band; 2) moderate form—a 75 to
120 ml/m2 RVEDV with localized hypokinetic or akinetic
and/or dyskinetic areas and/or trabecular disarrangement
and thickened, hyperechogenic or dense moderator band; 3)
Abbreviations and Acronyms
ARVC 5 arrhythmogenic right ventricular
cardiomyopathy
ARVD 5 arrhythmogenic right ventricular dysplasia
CHF 5 congestive heart failure
ECG 5 electrocardiogram
HFLA 5 high frequency low amplitude signal
duration in the terminal portion of the QRS
LBBB 5 left bundle branch block
LP 5 late potential
LV 5 left ventricular, left ventricle
PVB 5 premature ventricular beat
QRSD 5 filtered QRS duration
RBBB 5 right bundle branch block
RMS 5 root mean square of the voltage in the last
40 ms of the filtered QRS
RV 5 right ventricular, right ventricle
RVEDV 5 right ventricular end-diastolic volume
SAECG 5 signal averaged ECG
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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severe form—an RVEDV $120 ml/m2 with widespread
akinetic and/or dyskinetic areas of the RV and diastolic
bulging.
A SAECG was performed using a MAC 15 system
(Marquette Inc.; Milwaukee, Wisconsin). Time-domain
analysis was obtained in each patient using three different
filters at 25, 40, and 80 Hz. Methods have been previously
reported in detail (20,25). A SAECG was not obtained in
patients with bundle branch block (QRS duration
$110 ms). The normal values were (95% confidence inter-
val) for the 25-Hz filtered QRSD , 120 ms, HFLA ,
40 ms, RMS . 25 mV; for the 40-Hz filtered QRSD
,118 ms, HFLA , 40 ms, RMS . 20 mV; for the 80-Hz
filtered QRSD , 106 ms, HFLA , 34 ms, RMS . 12 mV.
The SAECG was considered positive when at least two
parameters were abnormal at one filter setting.
Other clinical testing (24-h ambulatory ECG, hemody-
namic study with endomyocardial biopsy, exercise stress
test, electrophysiologic study) has been described previously
(22–24). The exercise stress test was performed as a pro-
vocative test of arrhythmias. Ventricular arrhythmias re-
corded at standard ECG, during 24-h Holter monitoring or
during stress test examination, were subdivided into the
following: 1) VF; 2) sustained VT; 3) nonsustained VT; 4)
repetitive PVB couplets and triplets; and 5) frequent PVBs
(.30/h) (25).
DNA studies and linkage analysis. In 28 families, a
molecular genetic study was performed by linkage analysis.
Genomic DNA from available family members was ex-
tracted from blood samples according to the salting-out
procedure. A set of polymorphic markers closely linked to
ARVD1 (arrhythmogenic right ventricular dysplasia) locus,
to ARVD2, to ARVD3, to ARVD4 and to ARVD5 was
analyzed by polymerase chain reaction amplification according
to previously reported methods (9–14). Products were mixed
with an equal amount of formamide buffer, separated on
denaturing polyacrylamide gels, and the gels were silver
stained. Alleles were scored and haplotypes were generated.
Two-point lod scores between ARVD and these marker loci
were calculated with the MLINK program of the LINKAGE
package (vs. 5.2). Lod scores were calculated for two
different values of penetrance: 70% and 95%.
Statistical study. The chi-square or Fisher exact test was
used to assess the significance of differences between sub-
groups. Two-tailed p values ,0.05 were regarded as statis-
tically significant.
RESULTS
Among the 365 subjects, 151 (41.3%) were found to be
affected. Ninety-four were male (62%), and 57 were female
(38%) (p 5 0.02), with a gender ratio of 1.6:1 (vs. 1:1 of the
remaining family members). One hundred fifty-seven (43%)
individuals were unaffected. Seventeen patients (5%) had no
clinical evidence of the disease but could transmit it, so they
were considered healthy carriers. In the remaining 40
Figure 1. Number of affected patients among clinically evaluated subjects for each family in 37 affected families (black bar 5 affected patients).
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subjects (11%), the diagnosis was uncertain. The percentage
of affected patients among clinically evaluated subjects for
each family ranged from 33% to 75% (Fig. 1).
The age distribution of 19 probands who died suddenly is
shown in Figure 2 (mean, 27 6 10.5 years). Nine subjects
had a previous history of syncope (47%); 13 died during
effort (68%), 6 of whom had a previous syncopal episode. A
12-lead ECG tracing was available in 12 and showed
negative T waves in the precordial leads at least in V1–V3 in
42%: V1–V3 in 2 cases, V1–V5 in 1 and V1–V6 in 2. Four
subjects (33%) had negative T waves in the precordial leads
associated with ST segment elevation .2 mm; a complete
right bundle branch block (RBBB) was present in one, and
an incomplete RV delay with ST segment elevation .3 mm
in another case. The ECG was within normal limits in only
one patient. Analysis of pedigrees of the 37 affected families
showed that 20 additional subjects (14 male, 6 female) had
died suddenly at a young age (mean age, 27 6 10 years), and
2 had died from congestive heart failure (CHF), but without
postmortem investigation.
Clinical picture. Among the 132 living affected patients,
the disease has never been diagnosed in infancy, and only
twice under the age of 10 years (4 and 6 years old,
respectively). According to published criteria (19), affected
patients fulfilled at least the lowest score for the diagnosis of
ARVC, with the following distribution: four minor criteria
in 42 patients (32%); five minor criteria in 19 (14.5%); six
minor criteria in three (2%); one major, plus at least two
minor, criteria in 51 (38.5%); two major, plus at least two
minor, criteria in 11 (8.5%); and three major, plus at least
two minor, criteria in 6 (4.5%).
The mean age at diagnosis was 31 6 13 years (range, 4 to
64 years) (Fig. 3). The surface ECG was abnormal in 62
patients (47%): RBBB in 55 patients (complete in 5 and
incomplete in 50), inverted T waves in right precordial leads
(V1–V3 or more) in 24, and ST segment elevation .2 mm
in the right precordial leads in 18.
By comparing clinical data of the 19 probands who died
suddenly and the 132 living affected patients, we found that
there was a statistically significant difference only in terms of
previous history of syncope (42% vs. 18%; p , 0.001).
Sixty (45%) had ventricular arrhythmias: VF in 1, sus-
tained VT in 14; nonsustained VT in 8; PVB couplets and
triplets in 16 and frequent PVBs in 8 (.30/h), all with
LBBB morphology; exercise-induced polymorphic ventric-
ular arrhythmias were recorded in the remaining 13 pa-
tients. The age at the first recording of arrhythmias (mean,
28.5 6 12) is shown in Figure 3.
All affected patients had echocardiographic abnormali-
ties: 64% had a mild (85 cases, age 30.3 6 13.5 years), 30%
had a moderate form (39 cases, mean age 32.5 6 13.8 years)
and 6% had a severe form of the disease (8 cases, mean age
29.3 6 12.6 years) (Table 1). Among the 85 patients with
a mild form, 60 (70%) had evidence of RV motion abnor-
malities (i.e., hypokinesia or akinesia) in one or more areas:
the posterior wall underneath the tricuspid valve in 45, the
apex in 17 and the anterolateral free wall in 5 cases; 35
subjects (41%) had morphological changes. All 39 patients
with a moderate form had evidence of RV motion abnor-
malities in one or more areas: posterior wall underneath the
tricuspid valve in 24, the apex in 15 and the anterolateral
free wall in 9; 24 (61%) had evidence of morphological
Figure 2. Age of patients at time of sudden death. On the x-axis, the age of patients at the time of death; on the y-axis, the number of subjects.
Figure 3. Age of patients at time of diagnosis (black bars) and at time of onset of arrhythmias (gray bars). On the x-axis, the age of patients; on the y-axis,
the number of subjects.
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changes. Each of the eight patients with a severe form had
severe kinetic abnormalities of the RV posterior wall under-
neath the tricuspid valve, associated with apical in seven and
anterolateral free wall abnormalities in seven; morphological
changes were present in all. Right ventricular outflow
dilation was detected in 29% of the mild forms, 51% of the
moderate forms and 100% of the severe forms. Left ven-
tricular involvement was observed in 21 patients (16%), and
it was extensive only once.
Ventricular arrhythmias were present in all patients with
the severe form of the disease, in 82% with the moderate
form and in 23% with the mild form (Table 2).
Ninety-eight affected patients (77%) had late potentials
(LPs) at least at 80 Hz filter: in 100% of patients with the
severe form, in 97% with the moderate form and in 66%
with the mild form. Late potentials were also present in 10
of 157 healthy subjects. Moreover, LPs were present in 75%
of the affected patients with ventricular arrhythmias and in
78% of the affected patients without arrhythmias (p 5 NS)
(Table 3).
The maximal exercise stress test induced polymorphic
ventricular arrhythmias in 13 affected patients who did not
have arrhythmias at rest. In four patients with sustained VT,
the test triggered the same arrhythmias. Patients with
arrhythmias arising from the RV outflow tract had disap-
pearance of the arrhythmias during the test. In the remain-
ing patients, exercise stress test ECG did not modify the
arrhythmias.
All the affected patients were advised to avoid physical
exercise and sports activity. Forty-nine arrhythmic patients
were treated with antiarrhythmic drugs: 17 beta-blockers, 9
propafenone, 7 amiodarone, 6 sotalol, 5 beta-blockers 1
amiodarone, 2 beta-blockers 1 disopyramide, 2 flecainide
and 1 disopyramide. Patients with either VF or sustained
VT were treated with beta-blockers 1 amiodarone (5),
beta-blockers 1 disopyramide (2), amiodarone (2), sotalol
(2), and flecainide (1); the latter patient had sustained VT
originating from the RV outflow tract. Patients with effort-
induced polymorphic ventricular arrhythmias were treated
with beta-blockers (13). Two subjects with sustained VT
who did not respond to drug therapy had implantation of an
automatic cardioverter defibrillator. Nine affected patients
who did not have a severe form of the disease and did not
have LP or monomorphic nonsustained ventricular arrhyth-
mias, did not receive antiarrhythmic drug therapy. Radio-
frequency ablation has never been performed in this series of
patients.
Follow-up. The mean duration of follow-up was 8.5 6 4.6
years (range, 2 to 18 years). Fifteen subjects (age range, 8 to
21 years; mean age, 13 6 3 years) who were considered
unaffected at the first examination, later (mean age, 19 6 4
years) developed structural signs of ARVC at echocardiog-
raphy, and seven of them showed symptomatic ventricular
arrhythmias.
Seven affected patients who did not have ventricular
arrhythmias at the first examination showed frequent PVBs
(.30/h) during follow-up, while two patients with frequent
PVBs later developed sustained VT. Seven (5%) affected
patients who initially had a normal ECG tracing showed
ECG changes during the follow-up. Moreover, 10% of
patients later developed LP at SAECG. Four patients with
a mild form (5%) progressed to moderate disease, and three
Table 1. Echocardiographic Findings in 132 Affected Family Members
Mild Form
(85 Cases)
Moderate Form
(39 Cases)
Severe Form
(8 Cases)
RVEDV (ml/m2) 60 6 8 85 6 10 123 6 14
RVEF% 62 6 5 58 6 6 43 6 6
RV motion abnormalities (%) 70 100 100
RV posterior wall (%) 52 61 100
RV apical region (%) 20 38 87
RV anterolateral wall (%) 6 23 87
Morphological changes (%) 41 61 100
RV outflow dilatation (%) 29 51 100
LVEDV (ml/m2) 59 6 10 66 6 11 67 6 19
LVEF% 62 6 5 62 6 7 54 6 9
LV involvement (%) 7 25 62
RV 5 right ventricle; RVEDV 5 right ventricular end-diastolic volume; RVEF 5 right ventricular ejection fraction; LV 5 left
ventricle; LVEDV 5 left ventricular end-diastolic volume; LVEF 5 left ventricular ejection fraction.
Table 2. Correlation Between Arrhythmias and Extent of the Disease
Disease Extent
Arrhythmias
(%)
PVBs
>30/h
Repetitive
PVBs*
Nonsustained
VT
Sustained
VT
Effort-induced
Polymorphic
VA VF
Mild form (85 subjects) 23 4 2 2 1 11 0
Moderate form (39 subjects) 82 4 12 5 9 2 0
Severe form (8 subjects) 100 0 2 1 4 0 1
*Couplets and triplets.
PVBs 5 premature ventricular beats; VA 5 ventricular arrhythmias; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
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with a moderate form (8%) progressed to severe RV
involvement. Two patients developed LV involvement, with
diffuse abnormalities during the follow-up.
During this time interval, only one patient died suddenly.
He had a severe form of the disease and had stopped therapy
with amiodarone on his own 20 days before death. Thus, a
mortality rate of 0.08 patient/year was calculated in affected
patients.
Genetic study. The pedigree analysis of the 37 affected
families showed an autosomal dominant mode of inheri-
tance; both males and females can carry the disease and
transmit it. Among the 37 clinically evaluated families, 28
underwent linkage analysis so far. Six of them had the
disease locus mapped to chromosome 14q23-q24; in two
families, significantly positive lod scores were obtained with
markers closely linked to ARVD1 locus. In the other four
families, due to the size of the pedigrees, a lod score value
.3 was not obtained, but an at-risk haplotype defined by
the markers of the ARVD1 region was shared by all the
affected subjects and by none of the nonaffected subjects of
the same family. Four families were linked to ARVD2 locus
on chromosome 1q42-q43; a lod score of 5.3 for the marker
ACTN2 was obtained in one large family, while in the
remaining three families, the markers of the ARVD2 region
identified an haplotype invariably shared by all the affected
members and by none of the unaffected members. Four
families had the disease locus mapped to chromosome
2q32.1-q32.3; a maximum lod score value of 3.75 at q 5 0
for the marker D2S309 was obtained, and it was possible to
reconstruct an at-risk conserved haplotype. Four large fam-
ilies did not show linkage with any of the ARVD known
loci, providing evidence of further genetic heterogeneity.
The remaining 10 families have remained uninformative
due to their small size.
DISCUSSION
This study presents the findings of the largest systematic
investigation of familial ARVC studied over a long period
of time.
Clinical presentation of familial ARVC. The clinical
onset of ARVC clearly is postponed to adolescence and
young adulthood, thus supporting the concept of a disease
not present at birth with late phenotypic expression (1,19).
In fact, none of our familial cases was diagnosed in infancy,
and clinical onset, occurrence of arrhythmias and sudden
death showed a peak at the age interval of 16 to 35 years.
According to echocardiographic findings, the majority
(64%) had the mild form of the disease. We found that RV
abnormalities were frequently segmental, mostly in the
setting of normal RV volume, thus suggesting the need for
a careful echocardiographic investigation, focusing the at-
tention to the subtricuspid and infundibular region as well
as to subtle structural changes before ruling out ARVC. In
this regard, echocardiography is a well accepted imaging
technique employed for systematic investigation of family
members because it is both noninvasive and easily repro-
ducible, compared to angiography and isotopic methods.
It is noteworthy that in our series almost half of the cases
had a normal 12-lead ECG and 55% of affected patients had
no ECG-documented ventricular arrhythmias. Even
though the degree of “symptomatic” penetrance might be
low, the “true” penetrance of the disease was higher when
systematic investigation of affected families was carried out.
Thus, patients could have the concealed clinical phase of the
disease, even with definite RV structural changes. These
patients, in whom the arrhythmogenic substrate is present
but silent, may have subtle ECG and echocardiographic
signs of ARVC and LP by SAECG. In the context of a
positive family history, the combination of even minor
ECG and echocardiographic abnormalities is diagnostic.
The type and severity of arrhythmias were positively
correlated with the extent of the disease. Arrhythmias were
present in all subjects with the severe form and decreased
progressively in moderate and mild forms. All but one
patient with the moderate-severe form had LP on SAECG.
Sudden death was a frequent clinical presentation in the
family history, and most of these individuals had warning
symptoms and/or signs preceding the terminal event.
Diagnostic criteria in familial ARVC. Although either
noninvasive or invasive tests can readily confirm the pres-
ence of the overt form of the disease by revealing marked
dilation and/or aneurysmal bulges of the RV, in patients
with minimal anatomic changes such as mild enlargement
or even normal RV volume with only localized hypokinesia,
clinical recognition of ARVC is elusive. This is the major
challenge when dealing with clinical investigation of family
Table 3. Late Potentials Values Correlated With the Extent of the Disease and the Presence of Arrhythmias
LP No.
(%) LP at 80-Hz Filter
LP at 40-,
80-Hz-Filters
LP at 25-, 40-,
80-Hz Filters
Mild form (83*) 55 (66) 9 41 5
Moderate form (38*) 37 (97) 3 25 9
Severe form (6*) 6 (100) 0 2 4
Affected patients with arrhythmias (57*) 43 (75) 6 26 11
Affected patients without arrhythmias (70) 55 (78) 9 36 10
Healthy subjects (157) 10 (6) 4 4 2
Uncertain patients (39*) 8 (20) 3 5 0
Carriers (17) 1 (6) 0 0 1
*Patients with bundle branch block (QRS duration .100 ms) were excluded from this investigation.
LP 5 late potentials.
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members. Because the diagnostic criteria proposed by
McKenna et al. (19) have never been rigorously tested
within family members where there is by definition a much
higher probability of the disease, this study gave us the
opportunity to check their utility also in familial forms of
ARVC. Furthermore, because ARVC has an autosomal
dominant pattern of inheritance, the possibility of disease in
first-degree relatives is 50%, and within an affected family
the likelihood that minor ECG or echocardiographic ab-
normalities represent disease expression is higher than it
would be outside the context of proven familial disease. It is
noteworthy that although all our patients had a diagnosis of
ARVC according to task force criteria (19), a major crite-
rion was present in less than half of affected patients, and
one third reached only the lowest score (i.e., four minor
criteria). Moreover, because clinical expression of ARVC is
postponed to adolescence and young adulthood, the pro-
posed standard criteria for diagnosis cannot be applied until
after adolescent growth is completed, as supported by the
late appearance of the disease during follow-up in 15
formerly unaffected patients.
Long-term follow-up of familial forms. In contrast with
other published series dealing with the follow-up of non-
familial forms of ARVC (30–32), we never observed famil-
ial cases with CHF, despite the existence of severe forms at
echo. This might be explained by the low mean age of study
population and the relatively short-term follow-up. How-
ever, long-term progression toward CHF in some patients
cannot be excluded, because the pathobiology of the disease
is characterized by progressive loss of myocytes with late LV
involvement (16).
Occurrence of arrhythmic sudden death during the
follow-up was quite rare, with a mortality rate of 0.08
patient/year. By comparing available clinical data in pro-
bands who died suddenly and in affected living patients,
only a history of syncope seemed to be predictive of sudden
death. Prevalence of sudden death in patients with ARVC
has been variously reported in long-term follow-up studies.
Arrhythmic sudden death occurred in 2 of 15 (13%) patients
reported by Blomstrom-Lundqvist et al. (33) with a mean
follow-up of 8.8 years. A better outcome was observed in
the series by Leclercq and Coumel (34), with only 1 case of
sudden death out of 39 cases during a follow-up of 8.8 years;
in the series by Marcus et al. (35) there were no fatal events
in 16 patients during an 8.4-year follow-up. The apparent
contrast between a malignant family history and a benign
follow-up in our series may be explained by early diagnosis
of ARVC, exercise restriction and prompt treatment of
arrhythmic forms. Moreover, the favorable outcome may
depend on the fact that in more than half of families the
proband died suddenly, thus leading to survival of low risk
family members.
Management of familial forms. Because the identification
of subjects who are at high risk for sudden death has been
elusive, management of asymptomatic patients is still un-
clear, particularly in the setting of subtle morphological
abnormalities. Previous cardiac arrest, recurrent syncope,
severe RV and/or LV involvement and polymorphic sus-
tained VT seem to carry a worse long-term prognosis.
However, a minority of affected patients could remain
asymptomatic or suddenly develop life-threatening arrhyth-
mias and sudden death, especially upon effort. Usually we do
not treat asymptomatic patients with antiarrhythmic drugs
but rather recommend avoiding strenuous physical activity.
In patients with ventricular arrhythmias, antiarrhythmic
drug therapy might decrease the risk of sudden death, as
suggested by the very low mortality rate in our series as well
as in other previously reported studies (33–37). In our series,
type of drug was selected on the basis of the severity of
arrhythmias, extension of the disease, presence of LP at
SAECG and results of electrophysiologic study. Because
clinical findings that predict the long-term outcome of
ARVC patients is incompletely known, up to now there
have been no precise guidelines to select those who should
be treated with beta-blockers, antiarrhythmic drugs or
implantable cardioverter defibrillator, except for patients
with sustained VT or VF, in whom programmed ventricular
stimulation with serial drug testing should be performed
(38).
Genotype-phenotype correlation. The pedigree analysis
of these 37 affected families confirmed that both males and
females can carry and transmit the disease. The percentage
of affected subjects is almost 50% of family members, thus
supporting an autosomal dominant type of inheritance with
incomplete penetrance (7,8,39). Nevertheless, the preva-
lence of affected patients and severe forms of the disease is
higher in males than females. The same male/female ratio
was observed in patients who had died. It is likely that the
phenotypic expression of the disease is determined not only
by the genotype but also by environmental factors, favoring
a higher occurrence and expression in males.
The clinical findings may differ in the genetically distinct
forms of ARVC. Affected members of families with the
ARVD2 locus typically had effort-induced polymorphic
ventricular arrhythmias even in the setting of the mild form
of ARVC (40). As in other inherited heart diseases, an
influence of the genotype on the clinical manifestations and
course of ARVC is likely to occur.
CONCLUSIONS
Systematic study of family members and long-term
follow-up are bringing to light a less severe clinical form of
ARVC with a more favorable outcome than previously
thought. In the context of a positive family history, even
subtle ECG and echocardiographic abnormalities are diag-
nostic for ARVC. Clinical appearance during late adoles-
cence and young adulthood reinforces the concept of an
acquired and progressive myocardial atrophy not present at
birth.
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